Meeting proceedings

Friday 5 May 2017 - Day 1

  Session 1: Priorities in Biomarker Development for NASH
  
Chairs: Veronica Miller & Arun Sanyal
 

Tetri, Brent 2017 120

A pathologist, a radiologist and a hepatologist walked into a bar
Brent Tetri, MD
Saint Louis University Health Sciences Center, St. Louis, MO, USA

>Presentation
>Webcast

 

Innovation in histological assessment of NASH
Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France

>Presentation
>Webcast

 
  Session 2: Pathways to Biomarker Qualification and Acceptance
  
Chair: Chris Leptak & Veronica Miller
 

Stein, Peter 120

View from the Top - Potential impact of 21st Century Cures Act?
Peter Stein, MD
FDA Center for Drug Evaluation and Research, Silver Spring, MD 

>Presentation (not available)
>Webcast

 

EU Perspective
Elmer Schabel, MD
European Medicines Agency, London, UK & BfArM, Bonn, Germany

>Presentation
>Webcast (soon available)

 

Collaboration in action: BEST
Chris Leptak, MD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD

>Presentation
>Webcast

 

Collaboration in action: FNIH
Roberto Calle, MD, FACE, FACP
Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA

>Presentation
>Webcast

 

Collaboration in action: IMI
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom

>Presentation
>Webcast

 
  Session 3: Circulating biomarkers
 
 Chairs: Sudha Shankar & Brent Tetri
 

Puri, Puneet (from web) 120x160

Lipidomics and Proteomics
Puneet Puri, MD
Virginia Commonwealth University, Richmond, VA, USA

>Presentation (not available)
>Webcast

 

Role of Genetic assessments
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom

>Presentation
>Webcast

 

Francque, Sven 2017 120

Circulating nucleic acids and combination panels
Sven Francque MD, PhD
Antwerp University Hospital, Antwerp, Belgium

>Presentation
>Webcast

 
  Session 4: Imaging Biomarkers
  Chairs: Quentin Anstee & Lara Dimick-Santos
 

MRI; what can it deliver
Claude Sirlin, MD
UC San Diego, San Diego, CA, USA

>Presentation
>Webcast

 

Vuppalanchi, Raj 2016 120x160

Transient elastography & other techniques
Raj Vuppalanchi, MBBS
Indiana University School of Medicine, Indianapolis, IN, USA

>Presentation
>Webcast

 #01 - Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial
Michael Middleton, USA
>Presentation
 #02 - A meta-analysis on repeatability of magnetic resonance elastography of liver
Suraj Serai, USA
>Presentation
 

Saturday 6 May 2017 - Day 2

  Session 5: Quantative assessment of hepatic health
 
 Chairs: Roberto Calle & Puneet Puri
 

Siddiqui, Mohammed web 120

Breath tests
Shadab Siddiqui, MD, FACP
Virginia Commonwealth University, Richmond, VA, USA

>Presentation
>Webcast

 

Everson, Greg 2013

Principles of kinetic measures
Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, USA

>Presentation
>Webcast (soon available)

 #03 - A real-world, observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study
Miriam Vos, USA
 #04 - Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Alina Allen, USA
>Presentation 
 #06 - Serum GP73 as a surrogate biomarker of significant liver fibrosis and cirrhosis in NAFLD
Fengmin Lu, China
>Presentation
 #07 - Plasma collagen type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study
Diana Leeming, Denmark
>Presentation
 
  Session 6: Challenges Opportunities in integrating 'OMICS
  Chairs: Pierre Bedossa & Shadab Siddiqui
 

Schuck, Robert 2017 120

Big Data vs. the individual liver from a regulatory perspective
Robert Schuck, PharmD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA

>Presentation
>Webcast

 

Mato, Jose 2017 120

Big Data vs. the individual liver from a developer's perspective
José María Mato de la Paz, PhD
CIC BioGUNE, Derio, Spain

>Presentation (not available)
>Webcast

 

Travison, Tom 120

Future scenarios of algorithm building
Tom Travison, PhD
Harvard Medical School & Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA

>Presentation
>Webcast (not available)

 #08 - Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis
Sven Francque, Belgium
>Presentation
 #09 - A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH
Dean Hum, France
>Presentation (soon available)
 #10 - A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy
Pablo Ortiz, Spain
>Presentation
 
  Session 7: The Liver in Context
 
Chairs: Veronica Miller & Arun Sanyal
 

Sanyal, Arun 2015_def

Integrated Assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD
Arun Sanyal, MD, MBBS
Virginia Commonwealth University, Richmond, VA, USA

>Presentation
>Webcast

 

Sninsky, John 2017 120

Navigating NASH biomarkers: From discovery to clinical practice
John Sninsky, PhD
CareDx, Brisbane, CA, USA

>Presentation
>Webcast